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Abstract
Background: The amount of time spent living with disease greatly influences elderly people’s wellbeing, disability
and healthcare costs, but differs by disease, age and sex.
Methods: We assessed how various single and combined diseases differentially affect life years spent living with
disease in Dutch elderly men and women (65+) over their remaining life course. Multistate life table calculations
were applied to age and sex-specific disease prevalence, incidence and death rates for the Netherlands in 2007. We
distinguished congestive heart failure, coronary heart disease (CHD), breast and prostate cancer, colon cancer, lung
cancer, diabetes, COPD, stroke, dementia and osteoarthritis.
Results: Across ages 65, 70, 75, 80 and 85, CHD caused the most time spent living with disease for Dutch men
(from 7.6 years at age 65 to 3.7 years at age 85) and osteoarthritis for Dutch women (from 11.7 years at age 65 to 4.
8 years at age 85). Of the various co-occurrences of disease, the combination of diabetes and osteoarthritis led to
the most time spent living with disease, for both men (from 11.2 years at age 65 to 4.9 -years at age 85) and
women (from 14.2 years at age 65 to 6.0 years at age 85).
Conclusions: Specific single and multi-morbid diseases affect men and women differently at different phases in the
life course in terms of the time spent living with disease, and consequently, their potential disability. Timely sex and
age-specific interventions targeting prevention of the single and combined diseases identified could reduce
healthcare costs and increase wellbeing in elderly people.
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Background
The ultimate aim of healthcare should be to reduce dis-
ability and increase wellbeing [1]. Both disability and
wellbeing are broad concepts, however. Because disabil-
ity is usually defined as a limitation in physical or mental
functioning, caused by the presence of disease [2], the
amount of time spent with disease is an important factor
to consider when determining both disability and well-
being. The more time spent living with disease, the
higher the level of potential disability experienced, and
the higher the individual and healthcare related costs.
Reducing disability and the associated healthcare-
related costs becomes even more challenging with the
rapid ageing of populations in Western societies, par-
ticularly in Europe. Demographic projections indicate
that 30% of the European population will be aged 65 or
over by 2050 [3]. It is however clear that not all public
health interventions aimed at addressing morbidity and
longevity are effective [4]. Understanding which group
of elderly people should be targeted by disability/disease
prevention programmes is important for reducing the
burden of highly-prevalent diseases and combating
multi-morbidity among the elderly [5]. Timely interven-
tions targeted at vulnerable groups may be able to alter
undesirable health pathways and postpone disease devel-
opment [6]. This warrants a closer look into differences* Correspondence: BotesR@umcg.nl1Clinical Epidemiology, University Medical Centre Groningen, University of
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by disease, age and sex in time spent living with disease
and time spent living with comorbidity.
Many people aged 65 and older suffer from chronic
multi-morbid conditions associated with increased dis-
ability and reduced health-related quality of life
(HRQOL) [7]. Suffering from multi-morbidity also
causes elderly people to use healthcare resources more
often and to require more frequent hospitalization than
when suffering from a single disease [8].
Multi-morbidity and type of single chronic disease in-
fluence to a large extent the time spent living with dis-
ease [9, 10]. Diseases like COPD, cardiovascular disease
(CVD), dementia, diabetes and osteoarthritis are all dis-
eases which have a considerable impact on elderly peo-
ple’s disability and associated quality of life and
frequently occur together [11]. Future projections indi-
cate that high-income countries can expect ischemic
heart disease to account for 5.9% of the total disability-
adjusted life years by 2030. Other cardiovascular diseases
and COPD will account for 4.5% and 2.5% of the total
disability-adjusted life years in 2030 respectively [12].
Alongside chronic disease profiles including multi-
morbidity, age and gender also play an important role in
determining health transitions and the time spent living
with disability in elderly people [13–16]. Health transi-
tion typically refers to transition from a healthy state to
a diseased or disabled health state. It has been noted that
fewer elderly women are in good health than men, yet
women live longer than men [13]. Women are also more
likely to suffer from multi-morbidity compared to men
[13]. The experience of disease and disability from the
perspective of ‘young’ elderly people might also be very
different from older and very old elderly people. There-
fore, age and sex adjusted outcomes are needed to ef-
fectively plan for healthcare services for the aging
population [17].
Understanding the effect of different chronic diseases
and their co-occurrence on morbidity across the elderly
life course is essential to improve the provision of cost-
effective treatment options and taking into consideration
the variable effect of chronic disease on health transi-
tions in the male and female populations at different
older ages [17–19].
This study aims to assess how various single and multi-
morbid conditions will influence life years spent living
with disease for elderly in the Netherlands, thereby em-
phasizing differences between men and women and differ-
ences by age over the remaining life course.
Methods
Setting and data sources
We assessed the average remaining number of life years
that are expected to be spent living with various single
and combinations of diseases for Dutch men and women
aged 65, 70, 75, 80 and 85 in 2007.
Table 1 lists the specific diseases and disease combina-
tions we included in our study. The specific diseases
were chosen because they were the most prevalent
within the Dutch elderly population [20–22]. The dis-
ease combinations were included to demonstrate the ef-
fects of the combination of potentially fatal diseases
(CVD, cancer and COPD) and the combination of
mostly non-fatal diseases (osteoarthritis, dementia and
diabetes) (29;30). In doing so, a maximum of three dis-
eases were combined.
We obtained the health data below on the total popu-
lation in the Netherlands in 2007 by age (0–4, 5–9, …,
80–84, 85+) and sex. Population numbers and all-cause
and cause-specific death numbers were obtained from
Statistics Netherlands. Disease incidence rates and dis-
ease prevalence were obtained from the National Insti-
tute of Public Health and the Environment [23]. The
data were freely available to the public and, according to
Dutch legislation, no ethical approval was necessary to
perform the research.
Multistate life tables calculations
We applied multistate life table calculations to each dis-
ease and each disease combination. Multistate life table
calculations (often referred to as multistate life tables)
are an important demographic tool used to estimate the
expected average time spent in a given state from a
particular age, in our example the time spent living with
and without a particular disease (or disease combination).
Essentially, a multistate life table is an extension of the
general life table in which the expected (remaining) num-
ber of years of life (life expectancy) is assessed based on
age-specific mortality rates [24]. Multistate life tables,
however, compare more states than life and death, and
more transitions than just dying/mortality, and use age-
Table 1 Single and Multi-morbid disease combinations
Single disease Multi-morbid disease
Congestive heart failure (CHF) CHF + CHD
Coronary heart disease (CHD) Dementia + stroke
Breast cancer (women only) Diabetes + osteoarthritis
Prostate cancer (men only) CHF + osteoarthritis
Colon cancer CHF + CHD + diabetes
Lung cancer Dementia + stroke + CHF
Diabetes Dementia + stroke + lung cancer
Chronic obstructive
pulmonary disease (COPD)
Dementia + stroke + colon Cancer
Stroke Dementia + stroke + prostate cancer
Dementia Diabetes + osteoarthritis + dementia
Osteoarthritis CHF + osteoarthritis + COPD
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specific transition rates linked to the various transitions
as input for the calculations. In our case, we consid-
ered three states: 1) without a particular disease or
disease combination (non-diseased), 2) with a particu-
lar disease or disease combination (diseased), and 3)
death. We then distinguished three transitions: 1)
mortality from non-diseased to death, 2) mortality
from diseased to death, and 3) diseased from non-
diseased. We used the relevant age and sex-specific
transition rates as input: 1) mortality rates in the
non-diseased population calculated by dividing the
all-cause death numbers by the non-diseased popula-
tion, 2) mortality rates for the diseased population
calculated by dividing the cause-specific death num-
bers by the diseased population, and 3) the disease-
specific incidence rates. The diseased population was
calculated by multiplying disease prevalence by the
total population, and the non-diseased population was
obtained by subtracting the diseased population from
the total population.
Since the diseases considered are generally chronic, we
assumed no recovery and thus excluded the transition
from diseased to non-diseased.
We followed the life table calculations as described in
detail by Nusselder and Peeters [5, 25], which include
the following steps: 1) putting the rates in a matrix for-
mat for each age, 2) transforming the age-specific rate
matrices to age-specific probability matrices, 3) using in-
formation from the age-specific probability matrices as
input for the two life tables: one referring to the disease
state and the other to the non-diseased state, and 4) ap-
plying the normal life table calculations to the two life
tables to obtain the average remaining number of years
spent living either with or without the disease.
Like previous studies, we assumed that transition rates
were constant across the 5-year intervals. We applied the life
table calculations to five-year age groups starting at age 0,
and assumed that no one suffered from the studied diseases
and disease combinations at birth. For the number of years
spent living in the open ended age group for the various
states we used life expectancy at age 85 in 2007 from Statis-
tics Netherlands: 5.3 years for men and 6.6 years for women.
Multi-morbidity was estimated by combining single
disease transition rates by simple addition, without inter-
actions [21, 26]. For example, we estimated the multi-
morbidity of CHD and CHF by adding (1) the CHD inci-
dence rate to the CHF incidence rate, (2) the CHD
diseased death rate to the CHF diseased death rate,
and (3) the CHD non-diseased death rate to CHF
non-diseased death rate. Using the combined transi-
tion rates as input for the multistate life table calcula-
tions, we obtained the average number of years Dutch
men or women aged 65, 70, 75, 80, and 85 can ex-
pect to live with CHD and CHF combined.
Results
In 2007 Dutch men and women aged 65 could expect to
live another 17.4 and 20.9 years on average, respectively.
Of these remaining years, more years – compared to
other diseases – will be spent living with either osteo-
arthritis (7.1 years for men, 11.7 years for women), dia-
betes (7.0 and 6.5 years, respectively) and CHD (7.6 and
5.0 years, respectively (Table 2). The same applies to
Dutch people at older ages in 2007, although clear sex
differences appear. Men can expect to spend the most
years with CHD, starting from 7.6 years at age 65 to
3.7 years at age 85. Women can expect to spend the
most remaining years with osteoarthritis, starting from
11.7 years at age 65 to 4.8 years at age 85.
The share of remaining life time spent with disease in-
creases significantly from one age group to the next for
certain diseases, see Table 3.
The share of remaining life time spent with diabetes,
CHD and osteoarthritis increases significantly for men
from one age group to the next, whereas this is only true
for women with osteoarthritis. The share of remaining
life time spent living with stroke, dementia, colon cancer,
prostate/breast cancer and lung cancer does not change
much over the life course for men and women.
When considering the combination of diseases, older
Dutch men and women in 2007 could expect to live
most of their remaining life years with the ‘Diabetes +
osteoarthritis’ disease pair (Table 4). Dutch men aged 65
in 2017 can expect to live 11.2 years with diabetes and
osteoarthritis combined, and Dutch women aged 65,
14.2 years. At age 85, the figures are 4.9 years for men
and 6.0 years for women, respectively.
Again, important sex differences appear. Men can ex-
pect to spend more years with the ‘CHF + CHD’, ‘diabetes
+ osteoarthritis’ and ‘CHF + CHD + diabetes’ disease
combinations, while women can expect to spend more
years with ‘CHF + osteoarthritis’, ‘diabetes + osteoarth-
ritis’ and ‘CHF + osteoarthritis + COPD’.
The proportion of remaining life years spent with dis-
ease also increases progressively from one age group to
the next for the different combinations of diseases
(Table 5). The exceptions are dementia and stroke and
cancer combinations, where both men and women will
spend a similar percentage of their remaining life years
with disease from one age group to the next.
Despite the generally much lower share of remaining
life years spent living with disease at age 85 compared to
age 80, the share of remaining life years spent living with
disease combinations including dementia and stroke ac-
tually increases from age 80 to age 85.
Discussion
Across ages 65 and over, CHD caused the most time spent
living with disease for Dutch men and osteoarthritis for
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Dutch women. Of the various co-occurrences of disease,
the combination of diabetes and osteoarthritis led to the
most time spent living with disease, for both Dutch men
and women aged 65 and over.
Disease type and disease prevalence appear to be im-
portant factors when determining time spent living with
disease by elderly Dutch men and women.
Intuitively, diseases classified as non-fatal will cause
elderly men and women to spend more time living with
disease and disability and thus require more healthcare
resources, especially when these diseases are highly
prevalent. Osteoarthritis is not only considered non-fatal
but is also highly prevalent among Dutch elderly. Espe-
cially for elderly female patients osteoarthritis proved
Table 3 Share of remaining life time spent living with different single diseases (in percentages), for Dutch men and women aged
65, 70, 75, 80 and 85 in 2007
Age Diabetes CHF CHD COPD Osteoarthritis Dementia Lung Cancer Colon Cancer Prostate Cancer Stroke
Men
65 40.2 13.3 43.4 17.8 40.7 3.5 0.8 3.4 9.2 13.2
70 47.0 17.0 51.3 20.3 48.6 4.7 0.9 4.1 11.3 16.0
75 55.0 21.9 60.5 22.7 57.9 6.3 0.9 4.9 13.5 19.6
80 62.8 27.8 69.7 24.9 66.8 8.5 0.8 5.7 15.9 24.2
85+ 60.4 31.5 69.2 26.2 63.0 10.2 0.7 6.2 17.3 27.1
Women
65 31.0 9.9 24.0 20.1 55.8 4.7 0.3 2.3 7.8 9.8
70 34.9 12.0 27.9 22.1 63.1 5.9 0.3 2.6 8.4 11.5
75 39.5 15.0 32.5 24.2 71.1 7.6 0.3 3.0 9.0 13.5
80 43.8 18.6 37.1 26.2 76.9 9.5 0.2 3.4 9.7 15.6
85+ 45.2 21.4 39.8 27.4 73.1 11.1 0.2 3.6 10.3 17.3
Table 2 Total remaining life expectancy and remaining life expectancy spent living with different single diseases (in years), for
Dutch men and women aged 65, 70, 75, 80 and 85 in 2007
Remaining life expectancy spend with a certain diseasea
Age Remaining life
expectancyb









17.4 7.0 2.3 7.6 3.7 7.1 0.6 0.1 0.6 1.6 2.3
70
13.6 6.4 2.3 7.0 3.4 6.6 0.6 0.1 0.6 1.5 2.2
75
10.3 5.7 2.3 6.2 3.0 6.0 0.6 0.1 0.5 1.4 2.0
80
7.5 4.7 2.1 5.2 2.5 5.0 0.6 0.1 0.4 1.2 1.8
85
5.3 3.2 1.7 3.7 1.9 3.3 0.5 0.0 0.3 0.9 1.4
Women
65
20.9 6.5 2.1 5.0 4.2 11.7 1.0 0.1 0.5 1.6 2.1
70
16.8 5.9 2.0 4.7 3.7 10.6 1.0 0.1 0.4 1.4 1.9
75
12.9 5.1 1.9 4.2 3.1 9.2 1.0 0.0 0.4 1.2 1.7
80
9.5 4.2 1.8 3.5 2.5 7.3 0.9 0.0 0.3 0.9 1.5
85
6.6 3.0 1.4 2.6 1.8 4.8 0.7 0.0 0.2 0.7 1.1
aThe average number of remaining life years Dutch men or women in 2007 at the specified age can expect to live with a certain disease
bThe average number of remaining life years Dutch men or women in 2007 at the specified age can expect to live
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important in terms of the time spent with disease. Elim-
inating osteoarthritis and other non-fatal disorders
would result in savings in hospital care and nursing and
residential care facilities [27].
The fatal disease CHD causing the most time spent
living with disease for Dutch men could also be due to
the high prevalence of CHD in elderly men, but is also
the result of effective treatment, i.e. the increased health-
care resources allocated to the management of cardio-
vascular disease in the preceding years. This explanation
is in line with the considerable improvement of the sur-
vival rate of elderly CHD patients [28]. Also, diabetes is
a highly prevalent disease among elderly Dutch people,
but not necessarily fatal if controlled properly, which
could account for the increased time spent living with
disease by elderly diabetes patients. Clearly, the elimin-
ation of highly fatal diseases such as CHD but also neo-
plasms will not only result in a decrease in hospital care
costs, but also in an increase in time spent living with
the disease, and consequently increasing nursing and
residential care facilities costs.
Our results not only clearly indicate important differ-
ences between men and women in the impact of specific
individual and combined diseases, but also clear differ-
ences in their impact by age across the remaining life
course at age 65. The time Dutch elderly men spend
with either diabetes, CHD or osteoarthritis increases
progressively with age, and similarly for Dutch elderly
women with osteoarthritis. The various cancers, stroke
and dementia, however, do not show the same increas-
ing trend of disability over the life course of elderly
women. This clearly indicates that specific single dis-
eases affect elderly men and women differently at differ-
ent phases in the life course in terms of the time spent
living with disease, and consequently, their potential dis-
ability and quality of life. These important differences
need to be considered when planning for healthcare and
when designing interventions.
As far as multi-morbidity is concerned our results in-
dicate that both diabetes and osteoarthritis can be con-
sidered non-fatal diseases and the combination of these
two diseases can increase the time spent with disease.
Clearly, as far as the effect of multi-morbidity on mor-
bidity is concerned, the non-fatal combination of dia-
betes and osteoarthritis significantly reduces the
disability-free period elderly men and women will enjoy.
The multi-morbid disease combinations which include
dementia and stroke appear to be particularly ‘oldest old’
problems, since they increase the time men and women
spend with disease in the 80–84 and 85+ age groups.
Oostrom et al. have shown that individuals suffering from
multi-morbidity receive more face-to-face and telephone
Table 4 Total remaining life expectancy and remaining life expectancy spent living with different combinations of diseases (in
years), for Dutch men and women aged 65, 70, 75, 80 and 85 in 2007







































17.4 5.8 1.8 11.2 5.5 7.0 1.9 0.3 1.0 1.8 5.2 4.8
70
13.6 5.6 1.8 10.6 5.4 6.9 2.0 0.3 1.0 1.8 4.9 4.6
75
10.3 5.4 1.8 9.6 5.3 6.6 2.1 0.2 1.1 1.8 4.6 4.4
80
7.5 5.2 1.9 7.9 5.0 6.2 2.5 0.2 1.3 2.1 4.7 4.2
85
5.3 5.0 2.1 4.9 4.3 5.2 3.8 0.4 2.2 3.2 5.0 4.9
Women
65
20.9 4.8 2.3 14.2 9.1 6.8 2.4 0.4 1.3 2.2 7.9 8.6
70
16.8 4.7 2.2 12.9 8.4 6.4 2.4 0.4 1.3 2.1 7.1 7.9
75
12.9 4.5 2.1 11.2 7.6 6.0 2.4 0.4 1.3 2.0 6.2 7.2
80
9.5 4.2 2.0 9.0 6.5 5.6 2.5 0.4 1.3 1.9 5.6 6.4
85
6.6 3.9 1.9 6.0 5.3 5.4 3.1 0.5 1.6 2.4 5.7 5.9
aThe average number of remaining life years Dutch men or women in 2007 at the specified age can expect to live with a certain disease
bThe average number of remaining life years Dutch men or women in 2007 at the specified age can expect to live
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consultations with general practitioners, more minor opera-
tions, increased use of prescription medication, more home
visits and more referrals to specialized care [29]. People
with multi-morbidity may be receiving improved treatment
of their known conditions, which might also result in early
detection of additional diseases, increasing the survival rate
of elderly with multi-morbidity and extending the time
spent with disease.
We infer that, aside from the effects on health re-
source utilization, elderly people with multi-morbidity
may also be receiving better management of their multi-
morbid conditions because they use healthcare services
more frequently, effectively altering their disease pro-
gression and postponing mortality [30].
Since the prevalence rates of multi-morbid disease are
not readily available it is uncertain whether and to what
extent the prevalence rates of multi-morbid diseases
contribute to the time elderly Dutch people spend with
disease. However, it follows our choice to combine tran-
sition rates to estimate multi-morbid conditions that we
should assume that the prevalence of diseases and the
combinations thereof proportionally affect the time
spent with disease.
Understanding the effects of multi-morbid diseases on
the elderly male and female population could help
decision-makers plan appropriate pro-active and timely
interventions early in life to negate the negative effects
of multi-morbidity in later life.
In sum, information from studies like ours provide an
indication for sex- and age-specific interventions aimed at
the identified individual and combined diseases that cause
the most time spent living with disease by age and sex,
with as the ultimate aim to decrease disability across the
remaining life course of the elderly. Identifying and ac-
knowledging the effects of specific disease on elderly dis-
ability is only the first step in a remedial process.
Conceivably diseases like diabetes, osteoarthritis and CHD
can be cost-effectively managed or even avoided by alter-
ing unhealthy lifestyle choices, i.e. doing exercise or by
making healthy dietary choices. Identifying and under-
standing the social, cultural and economic barriers that
prohibit individuals from making or adhering to healthy
lifestyle choices, is however essential as well to address the
disability associated with specific diseases [31].
Educating health care services regarding important eld-
erly disease interactions and their implications can enhance
the effectiveness of interventions to diminish disability [32].
Strengths and limitations
A multi-state life table approach was used in this study
to provide an overview of the disability caused by disease
and multi-morbidity. A strength of this approach is the
Table 5 Share of remaining life time spent living with different combinations of diseases (in percentages), for Dutch men and




































33.3 10.3 64.4 31.6 40.2 10.9 1.7 5.7 10.3 29.9 27.6
70
41.2 13.2 77.9 39.7 50.7 14.7 2.2 7.4 13.2 36.0 33.8
75
52.4 17.5 93.2 51.5 64.1 20.4 1.9 10.7 17.5 44.7 42.7
80
69.3 25.3 105.3 66.7 82.7 33.3 2.7 17.3 28.0 62.7 56.0
85
94.3 39.6 92.5 81.1 98.1 71.7 7.5 41.5 60.4 94.3 92.5
Women
65
23.0 11.0 67.9 43.5 32.5 11.5 1.9 6.2 10.5 37.8 41.1
70
28.0 13.1 76.8 50.0 38.1 14.3 2.4 7.7 12.5 42.3 47.0
75
34.9 16.3 86.8 58.9 46.5 18.6 3.1 10.1 15.5 48.1 55.8
80
44.2 21.1 94.7 68.4 58.9 26.3 4.2 13.7 20.0 58.9 67.4
85
59.1 28.8 90.9 80.3 81.8 47.0 7.6 24.2 36.4 86.4 89.4
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use of data to provide a prospective view on disease pro-
gression and disability projections. Although the use of
combined transition rates to simulate multi-morbid con-
ditions is a simplification of the multi-morbidity interac-
tions, and 2007 data was implemented in this study, the
results of this study are supported by subsequent studies,
making the results significant and contributing to the ex-
pansion of knowledge in this research domain [33].
Firstly, the impact of the results can be substantial if
utilized by clinicians and other stakeholders, along with
results from similar studies within the healthcare sector
to plan cost-effective interventions for the current eld-
erly population. Preventive strategies for specific dis-
eases, as indicated by our results, can provide better
disability outcomes for the elderly and even delay the
onset of disability. Secondly, studies like ours can assist
decision-makers with difficult health resource allocation
decisions for future elderly populations.
Understanding how elderly men and women within
defined age groups will be affected by disease and multi-
morbidity is a valuable tool to provide effective and rele-
vant healthcare services to the elderly.
Conclusions
Specific single and multi-morbid diseases affect elderly
men and women differently at different phases in the life
course in terms of the time spent living with disease,
and consequently, their potential disability. Disease
prevalence, disease type and disease interactions are im-
portant factors in this regard.
Cost effective interventions and specialized treatment
regimens aimed at addressing specific diseases with a
high prevalence and multi-morbidity could increase eld-
erly people’s quality of life, while reducing disability and
healthcare costs for the elderly population.
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